MCM
WST icon

Moore Capital Management’s West Pharmaceutical WST Stock Holding History

Moore Capital Management’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-95,000
Closed -$26.1M – 826
2025
Q4 		$26.1M Hold
95,000
– – 0.38% 61
2025
Q3 		$24.9M Buy
+95,000
New +$23.1M 0.34% 72
2025
Q1 		– Sell
-63,000
Closed -$20.6M – 633
2024
Q4 		$20.6M Sell
63,000
-2,000
-3% -$629K 0.24% 109
2024
Q3 		$19.5M Sell
65,000
-15,000
-19% -$4.59M 0.36% 78
2024
Q2 		$26.4M Buy
80,000
+15,000
+23% +$5.3M 0.46% 70
2024
Q1 		$25.7M Buy
+65,000
New +$24M 0.41% 56
2023
Q2 		– Sell
-5,000
Closed -$1.73M – 604
2023
Q1 		$1.73M Buy
+5,000
New +$1.46M 0.04% 250

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Moore Capital Management's WST Position: Q1 2026 in Review

Moore Capital Management sold out of West Pharmaceutical (WST) in Q1 2026, closing a stake of 95,000 shares — an estimated $26.1M sold.

Moore Capital Management first reported a position in WST in Q1 2023 and held it in 7 quarters. The position peaked at $26.4M in Q2 2024. 755 funds tracked by Wall St. Rank hold WST as of Q1 2026.

  • Moore Capital Management reported no remaining West Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • Moore Capital Management sold 95,000 West Pharmaceutical shares in Q1 2026, an estimated $26.1M.
  • Moore Capital Management first reported a position in West Pharmaceutical in Q1 2023 and held it in 7 quarters.
  • Moore Capital Management's West Pharmaceutical position peaked at $26.4M in Q2 2024.
  • 755 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2026.

Based on Moore Capital Management's 13F filing for Q1 2026, filed 15 May 2026.